Alan T. Monroe
Papers
1
Total Citations
14
H-Index
1
About
Alan T. Monroe is a radiation oncologist whose work centers on the application of stereotactic body radiation therapy (SBRT) for the treatment of primary renal cell carcinoma. His major contribution lies in demonstrating the feasibility and safety of nephron-sparing radiosurgical approaches for patients with stage I kidney cancer, particularly those who are poor surgical candidates or who refuse surgery. In his most-cited paper from 2019, Monroe reported a single-institution experience with 21 patients, showing that SBRT can achieve effective tumor control while preserving renal function and minimizing toxicity. This work has garnered 14 citations and has helped establish SBRT as a viable non-invasive alternative to partial nephrectomy for select patients. Monroe’s research is notable for its prospective data collection on toxicity and efficacy, providing critical evidence that supports the broader adoption of this technique. By expanding treatment options for renal cell carcinoma, Monroe has contributed to a paradigm shift toward less invasive, organ-sparing therapies in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1